Navigation Links
Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011
Date:6/24/2011

focus our efforts on making this once-weekly therapy available to patients and healthcare providers in the U.S."

BYDUREON received marketing authorization in the European Union earlier this month. In the U.S., the FDA issued a complete response letter for the BYDUREON New Drug Application in late 2010. The companies plan to submit a response, including results of the thorough QT (tQT) study, in the second half of 2011. The tQT study uses intravenous exenatide to achieve plasma exenatide concentrations expected with BYDUREON, including the concentrations expected in patients with renal impairment.

BYDUREON is the proposed brand name for exenatide extended-release for injectable suspension. It is an investigational medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON is a once-weekly formulation of exenatide, the active ingredient in BYETTA® (exenatide) injection, which has been available in the U.S. since June 2005 and is used in more than 70 countries worldwide to improve glycemic control in adults with type 2 diabetes.

Analysis Design

This analysis included 148 patients with type 2 diabetes from the BYDUREON arm of DURATION-1, a phase 3, randomized, open-label, comparator-controlled trial. Electrocardiogram (ECG) recordings were performed at baseline; once steady-state plasma exenatide concentrations had been achieved following at least 14 weeks of treatment; and in a subset of patients at 30 weeks of treatment or sooner if the patient left the study early. Board-certified cardiologists who were blinded to treatment assignment performed analyses (interpretations) of all ECG tracings.

About Diabetes

Diabetes affects nearly 26 million people in the U.S. and an estimated 285 million adults worldwide.(ii, iii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes costs more than $174 billion per year in direc
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
2. Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
3. PRA Early Phase Leaders to Speak at Bioanalysis Forum
4. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
5. Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries
6. Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinsons Disease
7. ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
8. Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
9. Reportlinker Adds Hip Replacement Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
10. Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Reportlinker Adds Hearing Aid Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t63pbj/medical_device ) has announced the ... Markets Seminar" conference to their offering. ... well established, the next growth area is ... with other countries in this region have all implemented, ... medical device regulations. This seminar will provide a comprehensive ...
(Date:7/27/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... from institutional and accredited investors for a registered ... common stock and 3.35 million common stock purchase ...
(Date:7/27/2015)... , July 27, 2015  Cardica, Inc. (Nasdaq: CRDC ... its fiscal fourth quarter ended June 30, 2015, on Thursday, ... host a conference call at 4:30 p.m. Eastern Time to ... company,s business. Conference Call Details To access ... p.m. Eastern Time via phone, please dial 877-703-6106 from ...
Breaking Medicine Technology:Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2
... Candidate to Enter Clinical ... Studies in ... today it has initiated a Phase I clinical study of a ... safety, tolerability, and systemic pharmacokinetics of a topical,patch formulation of diclofenac ...
... Antisense Drug Targeting Glucagon Receptor for Treatment ... of Type 2 ... ) announced today it has earned $5,million from Ortho-McNeil, Inc. (OMI), a ... Phase 1,clinical trial of ISIS 325568. The collaboration between Isis and ...
Cached Medicine Technology:Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 2Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 3Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 2Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 3
(Date:7/27/2015)... ... 27, 2015 , ... On July 14, 2015, Harper’s Bazaar Magazine in an ... skin issues such as stretch marks , fine lines , and ... treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is ...
(Date:7/27/2015)... , ... July 27, 2015 , ... Eugene Batelli, D.P.M., ... accomplished athlete. “The patient is high-end athlete, whose accomplishments include running in 27 ... of Achilles tendon pain, which was diagnosed as tendinitis. I did an ultrasound ...
(Date:7/27/2015)... ... July 27, 2015 , ... The Maricopa Community Colleges today ... foster care system to get into and complete college. , The “Bridging Success ... an event today with partners from across the valley. , The initiative advisory board ...
(Date:7/27/2015)... New York, NY (PRWEB) , ... July 27, 2015 , ... ... North American tour. He will be performing for one additional night at each ... can add promo/coupon code DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America ...
(Date:7/27/2015)... , ... July 27, 2015 ... ... Global Calcium Propionate industry is a professional and in-depth research report. The ... industry chain structure, international market analysis etc. This report covers the global ...
Breaking Medicine News(10 mins):Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... cold virus to deliver pluripotent cells circumvents safety concerns, ... Researchers report that they have sidestepped a major technical ... adult cells. , A team of Boston scientists developed ... -- which are functionally similar to embryonic stem cells, ...
... to Eat Right, Move More and ... Milk Their Diets, NASHVILLE, Tenn., ... of different fad diets -- which seem to go in,and out of fashion ... three Americans -- including 27 percent of,Nashville residents -- remain overweight or obese., ...
... You Pink" campaign warns of "pinkwashing"., SAN ... respected watchdog of the breast cancer movement - ... Pink" campaign. The annual consumer,education campaign offers tips ... ( http://www.thinkbeforeyoupink.org ), This year,s campaign warns ...
... PHILADELPHIA, Sept. 25 The Council on Compulsive,Gambling of ... Systems Inc., and the Western Psychiatric Institute and,Clinic, our ... East Holiday Inn at 4751 Linden Road will host ... The Conference will be opened by,Tom Wolf, Secretary of ...
... 25 Sept. 26, 2008, marks the,100th anniversary ... 1908,Jersey City, N.J., was the first city in ... water. Since then, incidences of,waterborne diseases have plummeted, ... Director Gary Zimmerman,offers the following comments on behalf ...
... Employees Proves Worksite Wellness Programs Work, DALLAS, Sept. ... been recognized by the American Heart Association,s,Start! Fit-Friendly Companies ... place -- a 20 percent increase over last year., ... to get,Americans walking. Most adult Americans spend a majority ...
Cached Medicine News:Health News:Researchers Report Stem Cell Advance 2Health News:Researchers Report Stem Cell Advance 3Health News:Researchers Report Stem Cell Advance 4Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Tennessee Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Breast Cancer Action Targets Yoplait in 'Think Before You Pink' Campaign; Calls for Yogurt Without Artificial Hormones 2Health News:Statewide Gambling Conference -- Series of 'Firsts' -- Begins 9-30-08 2Health News:AWWA Marks 100th Anniversary of Chlorine Disinfection 2Health News:American Heart Association Announces Start! Fit-Friendly Companies 2Health News:American Heart Association Announces Start! Fit-Friendly Companies 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: